Akram Hernández-Vásquez1, Rodrigo Vargas-Fernández2, Guido Bendezu-Quispe3, Leandro Nicolás Grendas4. 1. Universidad Nacional Mayor de San Marcos. Lima, Peru; Universidad San Ignacio de Loyola, Vicerrectorado de Investigación, Centro de Excelencia en Investigaciones Económicas y Sociales en Salud. Lima, Peru. Electronic address: ahernandez@usil.edu.pe. 2. Universidad Científica del Sur. Lima, Peru. Electronic address: jrodrigovf1803@gmail.com. 3. Universidad San Ignacio de Loyola, Vicerrectorado de Investigación, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud. Lima, Peru. Electronic address: gbendezu@usil.edu.pe. 4. Instituto de Farmacología, Facultad de Medicina. Universidad de Buenos Aires. Buenos Aires, Argentina; Hospital General de Agudos "T. Álvarez". Buenos Aires, Argentina. Electronic address: leandrogrendas@hotmail.com.
Abstract
BACKGROUND: To date, the factors associated with the presence of depression or depressive symptoms in the Peruvian population have not been described. This study aimed to determine the prevalence of clinically relevant depressive symptoms in the Peruvian population and its associated factors. METHODS: A cross-sectional analytical study of secondary data from 2018 Demographic and Family Health Survey was conducted. The survey database includes 31,996 participants over 18 years of age. The dependent variable of the analysis was the presence of depression during the 14 days before the survey measured by the Patient Health Questionnaire (PHQ-9). Factors associated with the presence of depression were estimated with a proportional odds logistic regression model. RESULTS: The overall prevalence of clinically relevant depressive symptoms was 6.4% (moderate and severe symptomatology in 3.9% [95% CI: 3.6-4.3] and 2.5% [95% CI: 2.2-2.7], respectively). Being a woman, belonging to the age groups of 45 to 64 years or 65 or older, living in the Andean region, and having high blood pressure or diabetes mellitus or some disability increased the probability of having clinically relevant depressive symptoms. LIMITATIONS: The use of the PHQ-9 tool to assess depressive symptomatology limits the evaluation to a period of two weeks before the survey, requiring further study for diagnosis confirmation. CONCLUSION: Six out of 100 Peruvians presented moderate to severe clinically relevant depressive symptoms in 2018. Strategies for depression should contemplate population subgroups , such as women and patients with chronic diseases and disabilities.
BACKGROUND: To date, the factors associated with the presence of depression or depressive symptoms in the Peruvian population have not been described. This study aimed to determine the prevalence of clinically relevant depressive symptoms in the Peruvian population and its associated factors. METHODS: A cross-sectional analytical study of secondary data from 2018 Demographic and Family Health Survey was conducted. The survey database includes 31,996 participants over 18 years of age. The dependent variable of the analysis was the presence of depression during the 14 days before the survey measured by the Patient Health Questionnaire (PHQ-9). Factors associated with the presence of depression were estimated with a proportional odds logistic regression model. RESULTS: The overall prevalence of clinically relevant depressive symptoms was 6.4% (moderate and severe symptomatology in 3.9% [95% CI: 3.6-4.3] and 2.5% [95% CI: 2.2-2.7], respectively). Being a woman, belonging to the age groups of 45 to 64 years or 65 or older, living in the Andean region, and having high blood pressure or diabetes mellitus or some disability increased the probability of having clinically relevant depressive symptoms. LIMITATIONS: The use of the PHQ-9 tool to assess depressive symptomatology limits the evaluation to a period of two weeks before the survey, requiring further study for diagnosis confirmation. CONCLUSION: Six out of 100 Peruvians presented moderate to severe clinically relevant depressive symptoms in 2018. Strategies for depression should contemplate population subgroups , such as women and patients with chronic diseases and disabilities.
Authors: Victoria Guazzelli Williamson; Estelle L Berger; Marjolein E A Barendse; Jennifer H Pfeifer; Ronald E Dahl; Lucía Magis-Weinberg Journal: Res Child Adolesc Psychopathol Date: 2022-06-08
Authors: Daniel A Antiporta; Yuri L Cutipé; Maria Mendoza; David D Celentano; Elizabeth A Stuart; Andrea Bruni Journal: BMC Psychiatry Date: 2021-02-18 Impact factor: 3.630
Authors: Catherine Porter; Marta Favara; Annina Hittmeyer; Douglas Scott; Alan Sánchez Jiménez; Revathi Ellanki; Tassew Woldehanna; Le Thuc Duc; Michelle G Craske; Alan Stein Journal: BMJ Open Date: 2021-04-15 Impact factor: 2.692
Authors: Charlie F M Pitcairn; Anthony A Laverty; Jasper J L Chan; Oyinlola Oyebode; Matías Mrejen; Julia M Pescarini; Daiane Borges Machado; Thomas V Hone Journal: Epidemiol Psychiatr Sci Date: 2021-10-21 Impact factor: 7.818
Authors: Maciej Polak; Grzegorz Józef Nowicki; Katarzyna Naylor; Robert Piekarski; Barbara Ślusarska Journal: Int J Environ Res Public Health Date: 2022-09-19 Impact factor: 4.614